Repare Therapeutics Inc. (RPTX) Provides Business and Clinical Update

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/6/2026

1. PTC
2. NVDA
3. PCVX
4. META
5. MSFT
6. SPY
7. GOOGL
8. GMAB
9. USO
10. AMD

Go back to Repare Therapeutics Inc. (RPTX) Provides Business and Clinical Update

Repare Therapeutics Provides Business and Clinical Update and Reports Fourth Quarter and Full Year 2024 Financial Results

March 3, 2025 7:05 AM EST

Initial clinical readout from Phase 1 RP-3467 (Pol ATPase/helicase inhibitor) POLAR trial expected in Q3 2025

Initial clinical readout from Phase 1 RP-1664 (PLK4 inhibitor) LIONS trial expected in Q4 2025

Company reducing its workforce by approximately 75%

$152.8 million in cash and cash equivalents and marketable securities provides runway to late-2027

Exploring partnerships across portfolio, including for Lunre+Camo

CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)-- Repare Therapeutics Inc. (Repare or the Company) (Nasdaq: RPTX), a clinical-stage precision oncology company, today reported... More